Nuvo Research's US Pennsaid Saga Ends Happily >NRI.T

Nov 5th, 2009 - Wall Street Journal

Related content:

TORONTO (Dow Jones)--It's taken the better part of a decade, but Nuvo Research Inc. (NRI.T) has finally landed U.S. approval of its topical pain medicine, Pennsaid.

Earlier Thursday, the Canadian biotech - formerly known as Dimethaid - said the U.S. Food and Drug Administration approved Pennsaid for the treatment of "the signs and symptoms of osteoarthritis of the knee." The approval triggers a ...

Read the whole story on Wall Street Journal or try our Toolbar

blog comments powered by Disqus

FDA warns against erectile dysfunction supplement
Nov 6th, 2009 - Los Angeles Times
The Food and Drug Administration is warning consumers that Stiff Nights, a "dietary supplement" used to promote erections, contains an illegal drug and is potentially dangerous. Following a complaint...
BEFORE THE BELL-Sunesis shares rally after FDA move
Nov 5th, 2009 - Forbes
NEW YORK, Nov 5 (Reuters) - Shares of Sunesis Pharmaceuticals rose 45 percent to 55 cents in premarket trading on Thursday, after the company said one of its drugs had received orphan drug designation from the Food and Drug Administration.
FDA Says Companies Violating Flavored Cigarette Ban
Nov 6th, 2009 - ABC News
WASHINGTON (Reuters) - U.S. regulators warned 10 companies for violating a recently enacted ban on sales of flavored cigarettes, letters released on Friday showed. The Food and Drug Administration told Clove Cigarettes Shop...
FDA Warning: Over-the-Counter Sex Enhancement Drug May Cause 'Dangerously' Low Blood Pressure
Nov 6th, 2009 - FOXNews
The U.S. Food and Drug Administration is warning consumers that "Stiff Nights," a product marketed as a dietary supplement for sexual enhancement, contains an ingredient that can dangerously lower blood pressure and is illegal.
UPDATE 2-Boston Scientfic reaches pact with DOJ, shares fall
Nov 6th, 2009 - Reuters
* Reaches agreement with U.S. DOJ over Guidant advisories * To pay $296 million as part of deal * Will record Q3 charge of $294 million * Sees FY09 adjusted shr at 75-79 cents...